Internal Medicine, Hematology & Oncology · Los Angeles, CA
NPI
1417132499
Since 2008
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
2
Hospital affiliations
2080 Century Park E Ste 1005
Los Angeles, CA, 90067
Phone (310) 229-3535
Groups this clinician bills Medicare through
Medicare paid, 2024
$5.0M
215,344 services
Medicare patients, 2024
1,280
Average age 76
Drug cost, 2024
$8.9M
2,543 prescriptions
Company payments, 2025
$4,541
From 44 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Shahrooz Eshaghian was code J0897 (injection, denosumab, 1 mg), 24,751 times for 154 patients. In total Shahrooz Eshaghian billed 215,344 services in 115 codes, and Medicare paid $5.0M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-03-07.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 24,751 | 154 | $20.66 | $511K |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 11,800 | 98 | $15.74 | $186K |
| J9271 Injection, pembrolizumab, 1 mg | Office | 11,207 | 11 | $44.39 | $498K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 6,940 | 131 | $0.09 | $625 |
| 99232 Hospital E&M - Subsequent | Facility | 5,771 | 604 | $64.59 | $373K |
| 85025 Blood Count | Office | 2,341 | 623 | $7.57 | $18K |
| 36415 Venipuncture Blood Collection | Office | 2,209 | 617 | $8.59 | $19K |
| 80048 Clinical Chemistry | Office | 2,117 | 599 | $8.24 | $17K |
| 99214 Office E&M - Established | Office | 2,115 | 684 | $103.24 | $218K |
| 80076 Clinical Chemistry | Office | 2,103 | 600 | $7.97 | $17K |
| 96127 Behavioral Health Services | Office | 1,304 | 718 | $3.81 | $4,972 |
| 96372 Injection Administration | Office | 1,040 | 270 | $11.72 | $12K |
| 99233 Hospital E&M - Subsequent | Facility | 1,013 | 441 | $97.17 | $98K |
| 82728 Clinical Chemistry | Office | 976 | 486 | $13.28 | $13K |
| 99223 Hospital E&M - Initial | Facility | 795 | 625 | $141.89 | $113K |
By year: 2022 $3.1M for 324,059 services; 2023 $4.1M for 258,108 services; 2024 $5.0M for 215,344 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 2,341 | 623 | $7.57 | $18K |
| 36415 Venipuncture Blood Collection | 2,209 | 617 | $8.59 | $19K |
| 80048 Clinical Chemistry | 2,117 | 599 | $8.24 | $17K |
| 80076 Clinical Chemistry | 2,103 | 600 | $7.97 | $17K |
| 82728 Clinical Chemistry | 976 | 486 | $13.28 | $13K |
| 82378 Clinical Chemistry | 580 | 161 | $18.58 | $11K |
| 82607 Clinical Chemistry | 517 | 373 | $14.64 | $7,569 |
| 82746 Clinical Chemistry | 488 | 371 | $14.30 | $6,976 |
| 85379 Clinical Chemistry | 454 | 183 | $9.96 | $4,521 |
| 84481 Clinical Chemistry | 401 | 170 | $16.56 | $6,640 |
Medicare prescription drug claims, 2024
In 2024, the drug Shahrooz Eshaghian prescribed most often to Medicare patients was Eliquis (Apixaban), with 366 prescriptions and refills. In total Shahrooz Eshaghian wrote 2,543 Medicare prescriptions that cost $8.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Eliquis Apixaban | 366 | 458 | 77 | $265K |
| Procrit Epoetin Alfa | 137 | 137 | 26 | $197K |
| Orgovyx Relugolix | 107 | 107 | 15 | $350K |
| Dutasteride Generic | 95 | 249 | 30 | $3,058 |
| Acyclovir Generic | 94 | 112 | 15 | $1,718 |
| Prednisone Generic | 81 | 85 | 18 | $440 |
| Dexamethasone Generic | 81 | 105 | 18 | $1,309 |
| Ninlaro Ixazomib Citrate | 56 | 56 | Under 11 | $701K |
| Pomalyst Pomalidomide | 55 | 55 | Under 11 | $1.3M |
| Hydroxyurea Generic | 52 | 88 | 12 | $678 |
| Rosuvastatin Calcium Generic | 49 | 127 | 15 | $1,130 |
| Letrozole Generic | 47 | 101 | 13 | $1,261 |
| Abiraterone Acetate Generic | 45 | 45 | Under 11 | $106K |
| Ondansetron Hcl Generic | 39 | 42 | 26 | $578 |
| Levothyroxine Sodium Generic | 38 | 88 | Under 11 | $452 |
Brand drugs: 1,321 claims; generic drugs: - claims; opioid claims: 25.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Shahrooz Eshaghian $4,541 ($4,541 in general payments such as food, travel and fees) from 44 companies. The largest payer was Janssen Biotech, Inc. with $359.
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. JNJ | 26 | $359 |
| AstraZeneca Pharmaceuticals LP AZN | 11 | $288 |
| E.R. Squibb & Sons, L.L.C. BMY | 24 | $269 |
| Merck Sharp & Dohme LLC MRK | 9 | $256 |
| Genzyme Corporation SNY | 6 | $254 |
| Daiichi Sankyo Inc. 4568.T | 19 | $238 |
| Pfizer Inc. PFE | 13 | $237 |
| Celgene Corporation BMY | 20 | $201 |
| Genentech USA, Inc. ROG.SW | 17 | $198 |
| Novartis Pharmaceuticals Corporation NVS | 13 | $183 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.